Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-04-25
2011-12-13
Goddard, Laura B (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
08076304
ABSTRACT:
The present invention relates to compositions and methods for cancer therapeutics. In particular, the present invention provides compositions and methods for inhibiting cancer metastasis by inhibiting cyclin A1.
REFERENCES:
patent: 6506559 (2003-01-01), Fire et al.
patent: 7153700 (2006-12-01), Pardee et al.
patent: 2006/0019256 (2006-01-01), Clarke et al.
patent: WO0198537 (2001-12-01), None
Qi et al (Cancer Research, 2003, 63:8323-8329).
Yu et al (Nature Medicine, Feb. 2004; Epub Jan. 4, 2004; 10:175-181).
Colette et al (PNAS, Apr. 2004, 101:6478-6483).
Katoh et al (Nucleic Acids Research, Supplement No. 3, 2003, p. 249-250).
Chopra et al (Targets, Sep. 2002, 1:102-108).
Aoki et al (Clinical and Experimental Pharmacology and Physiology, 2003, 30:96-102).
Li et al (Nature, 2003, 426:247-254).
Relaix et al.,“From insect eye to vertebrate muscle: redeployment of a regulatory network.”(1999) Genes Dev 13, 3171-8.
Ozaki et al., “Six1controls patterning of the mouse otic vesicle.”(2004) Development 131, 551-62.
Zheng et al., “The role ofSix1in mammalian auditory system development”(2003) Development 130, 3989-4000.
Zuber et al:, “Giant eyes inXenopus laevisby overexpression ofXOptx2” (1999) Cell 98, 341-52.
Goudreau et al., “Mutually regulated expression of Pax6 and Six3 and its implications for the Pax6 haploinsufficient lens phenotype” (2002) Proc Natl Acad Sci USA 99, 8719-24.
Laflamme et al., The homeotic protein Six3 is a coactivator of the nuclear receptor NOR-1 and a corepressor of the fusion protein EWS/NOR-1 in human extraskeletal myxoid chondrosarcomas, Cancer Res, 63 p. 449-454 (2001).
Winchester at al., “Expression of a homeobox gene (SIX5) in borderline ovarian tumours”(2000) J Clin Pathol 53, 212-7.
Li et al., “Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition”(2002) Am J Pathol 160, 2181-90.
Khan et al., “cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene” (1999) Proc Natl Acad Sci U S A 96, 13264-9.
Ford et al., “Abrogation of the G2 cell cycle checkpoint associated with overexpression of HSIX1: a possible mechanism of breast carcinogenesis”(1998) Proc Natl Acad Sci U S A.
Laclef et al., “Altered myogenesis inSix1-deficient mice”(2003) Development 130, 2239-52.
Liu et al., “Cyclin A1 is required for meiosis in the male mouse” (1998) Nat Genet 20, 377-80.
Geng et al., “Cyclin E ablation in the mouse” (2003) Cell 114, 431-43.
Luzzi et al., “Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases”(1998) Am Jof Pathology, 153:865 (1998).
Tuschl “Small interfering RNAs: a revolutionary tool for the analysis of gene function and gene therapy” Molecular Intervent. 2002; 2(3):158-67.
Caplen et al, “Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems” Proc Natl Acad Sci U.S.A. 2001; 98: 9742-7.
Elbashir et al., “Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells” Nature. 2001; 411:494-8.
Elbashir et al., “RNA interference is mediated by 21- and 22-nucleotide RNAs” Genes Dev. 2001;15: 188-200.
Elbashir et al., “Functional anatomy of siRNAs for mediating efficient RNAi inDrosophila melanogasterembryo lysate” EMBO J. 2001; 20: 6877-88.
Holen et al, “Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor” Nucleic Acids Res 2002; 30:1757-66.
Gurrieri et al., “Loss of the tumor suppressor PML in human cancers of multiple histologic origins” (2004) Journal of the National Cancer Institute 96, 269-79.
Guo et al., “A novel DNA damage checkpoint involving post-transcriptional regulation of cyclin A expression” (2000) J Biol Chem 275, 1715-22.
Yang et al., (1999) Blood 93, 2067-74.
Romanowski et al., “Interaction ofXenopusCdc2 x cyclin A1 with the origin recognition complex” (2000) J Biol Chem 275, 4239-43.
Muller et al., “Cloning of the cyclin A1 genomic structure and characterization of the promoter region. GC boxes are essential for cell cycle-regulated transcription of the cyclin Al gene” (1999) J Biol Chem 274, 11220-8.
Spitz et al., “Expression of myogenin during embryogenesis is controlled by Six/sine oculishomeoproteins through a conserved MEF3 binding site” (1998) Proc Natl Acad Sci U S A 95, 14220-5.
Sweeney et al., “A distinct cyclin A is expressed in germ cells in the mouse” (1996) Development 122, 53-64.
Yang et al., “Functions of cyclin A1 in the cell cycle and its interactions with transcription factor E2F-1 and the Rb family of proteins” (1999) Mol Cell Biol 19, 2400-7.
Ford et al., “Cell cycle-regulated phosphorylation of the human SIX1 homeodomain protein” (2000) The Journal of Biological Chemistry 275, 22245-22254.
Agami et al., “Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage” (2000) Cell 102, 55-66.
Sauk et al., “Hsp47 and the translation-translocation machinery cooperate in the production of alpha 1(1) chains of type I procollagen” (1994) J Biol Chem 269, 3941-6.
Coletta Ricardo D.
Ford Heide L.
Lamb Justin
Pardee Arthur R.
Goddard Laura B
Medlen & Carroll LLP
The Regents of the University of Colorado
LandOfFree
Methods and compositions for the diagnosis and treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the diagnosis and treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the diagnosis and treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4254370